Sam Brusco, Associate Editor05.02.23
Insight Medbotics, a company combining MRI accuracy with robotic precision, has appointed Fazila Seker as its new CEO, and she will serve on the company’s board of directors. Seker replaces Paul Chipperton, who was the company’s CEO and president for two years.
Insight Medbotics is developing MRI-guided robotics to combine the insights of MRI with the minimally invasive access and precision of robotics. The company’s MRI-compatible IGAR robot has clinically demonstrated use in breast biopsies for breast cancer patients. According to the company, other possible uses include therapeutic delivery and device placement.
Seker previously served as program leader for GE Global Research Center in Niskayuna, N.Y., as well as director of technology and venture development for MaRS Innovation in Toronto. She was also president and CEO of MOLLI Surgical from 2018 to 2022.
Seker led MOLLI Surgical through FDA and Health Canada clearance for its flagship breast cancer surgery product.
"We are delighted to welcome Fazila as Insight Medbotics' new CEO,” Dean Mosca, Chairman of the Board of Directors, Insight Medbotics, told the press. “Her track record in the medical devices space, particularly in bringing early-stage technology to market while fostering strong, collaborative corporate cultures, made her an ideal choice."
"I'm excited to join Insight Medbotics' team during this unprecedented era in healthcare,” added Seker. “The convergence of more accessible MRI imaging, artificial intelligence and robotics together offer unique opportunities for our technology to improve quality of life for patients. I believe great teams do great things, and the quality of our board and clinical advisors gives me confidence in our ability to impact people's lives in ways that weren't possible before."
Insight Medbotics is developing MRI-guided robotics to combine the insights of MRI with the minimally invasive access and precision of robotics. The company’s MRI-compatible IGAR robot has clinically demonstrated use in breast biopsies for breast cancer patients. According to the company, other possible uses include therapeutic delivery and device placement.
Seker previously served as program leader for GE Global Research Center in Niskayuna, N.Y., as well as director of technology and venture development for MaRS Innovation in Toronto. She was also president and CEO of MOLLI Surgical from 2018 to 2022.
Seker led MOLLI Surgical through FDA and Health Canada clearance for its flagship breast cancer surgery product.
"We are delighted to welcome Fazila as Insight Medbotics' new CEO,” Dean Mosca, Chairman of the Board of Directors, Insight Medbotics, told the press. “Her track record in the medical devices space, particularly in bringing early-stage technology to market while fostering strong, collaborative corporate cultures, made her an ideal choice."
"I'm excited to join Insight Medbotics' team during this unprecedented era in healthcare,” added Seker. “The convergence of more accessible MRI imaging, artificial intelligence and robotics together offer unique opportunities for our technology to improve quality of life for patients. I believe great teams do great things, and the quality of our board and clinical advisors gives me confidence in our ability to impact people's lives in ways that weren't possible before."